Neurogene to Present NGN-401 Trial Data for Rett Syndrome at CNS Meeting
Portfolio Pulse from Benzinga Newsdesk
Neurogene Inc. (NASDAQ:NGNE) will present interim efficacy and safety data from its NGN-401 gene therapy trial for Rett syndrome at the CNS Annual Meeting. The presentation will include data from both low- and high-dose cohorts.
October 21, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurogene Inc. is set to present important interim data from its NGN-401 gene therapy trial for Rett syndrome, which could influence investor sentiment and stock price.
The presentation of interim efficacy and safety data from the NGN-401 trial is a significant event for Neurogene, as it could impact investor perception and the company's stock price. Positive data could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100